INOVIO PHARMACEUTICALS INC (INO)
US45773H4092 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 14.31M | 46.30M | 71.10M | 250.70M | 22.20M | |||
| Marketable Securities | 130.98M | 206.70M | 330.20M | 160.90M | 67.30M | |||
| Receivables | 2.41M | 11.70M | 8.00M | 19.10M | 2.00M | |||
| Other Current Assets | 5.41M | 50.50M | 39.10M | 40.50M | 2.60M | |||
| Total Current Assets | 153.11M | 315.20M | 448.40M | 471.20M | 94.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 14.45M | 18.00M | 29.00M | 24.10M | 26.60M | |||
| Investments And Advances | 2.78M | 2.00M | 3.90M | 4.90M | 6.30M | |||
| Goodwill | 0.00 | 10.50M | 10.50M | 10.50M | 10.50M | |||
| Intangibles | 0.00 | 2.10M | 2.60M | 3.10M | 3.70M | |||
| Other Non-Current Assets | 605.32K | 700.00K | 1.40M | 26.00M | 2.70M | |||
| Total Non-Current Assets | 17.84M | 33.30M | 47.50M | 68.60M | 49.80M | |||
| TOTAL ASSETS | 170.95M | 348.50M | 495.90M | 539.80M | 144.00M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 16.77M | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 21.04M | 29.20M | 36.40M | 32.70M | 17.40M | |||
| Accounts Payable | 4.65M | 65.10M | 24.70M | 1.40M | 7.60M | |||
| Other Current Liabilities | 109.41K | 2.60M | 4.60M | 7.60M | 6.90M | |||
| Total Current Liabilities | 42.57M | 96.90M | 65.70M | 41.70M | 32.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 16.60M | 15.00M | 18.70M | 77.00M | |||
| Deferred Taxes/Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 11.03M | 12.70M | 15.50M | 18.20M | 29.50M | |||
| Total Non-Current Liabilities | 11.03M | 29.30M | 30.60M | 36.90M | 108.50M | |||
| TOTAL LIABILITIES | 53.60M | 126.20M | 96.30M | 78.60M | 140.50M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.62B | -1.49B | -1.21B | -906.20M | -739.80M | |||
| Additional Paid In Capital | 1.74B | 1.71B | 1.61B | 1.37B | 742.60M | |||
| Minority Interest | N/A | 0.00 | 0.00 | 1.06M | 3.19M | |||
| Common Shares | 22.79K | 300.00K | 200.00K | 200.00K | 100.00K | |||
| Other Shareholders' Equity | -662.60K | -700.00K | -300.00K | -300.00K | 500.00K | |||
| Shares Outstanding | 22.79M | 253.10M | 217.40M | 186.90M | 101.40M | |||
| Tangible Book Value per Share | 5.15 | 0.83 | 1.78 | 2.39 | -0.11 | |||
| Total Shareholders' Equity | 117.35M | 222.40M | 399.70M | 461.10M | 3.40M | |||
| TOTAL LIABILITIES AND EQUITY | 170.95M | 348.50M | 495.90M | 539.80M | 144.00M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | 0.07 | 0.04 | 0.04 | 22.65 | |||
| Current Ratio | 3.60 | 3.25 | 6.82 | 11.30 | 2.94 | |||
| Return On Assets (ROA) | -79.04% | -80.29% | -61.23% | -30.83% | -82.89% | |||
| Return On Equity (ROE) | -115.14% | -125.82% | -75.97% | -36.09% | -3510.59% | |||
All data in USD